TLSA
HEALTHCARETiziana Life Sciences Ltd
$1.47+0.04 (+2.80%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TLSA Today?
No stock-specific AI insight has been generated for TLSA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.14$2.60
$1.47
Fundamentals
Market Cap$187M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-9.2%
Profit Margin—
Debt / Equity—
Trading
Volume184K
Avg Volume (10D)—
Shares Outstanding127.3M
TLSA News
20 articles- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationYahoo Finance·Apr 22, 2026
- Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”Proactive Investors·Apr 16, 2026
- Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionGlobeNewswire Inc.·Apr 16, 2026
- Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressYahoo Finance·Apr 14, 2026
- Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson CongressProactive Investors·Apr 14, 2026
- Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingYahoo Finance·Apr 1, 2026
- Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAYahoo Finance·Feb 25, 2026
- While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownershipYahoo Finance·Feb 9, 2026
- Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal ForalumabYahoo Finance·Jan 20, 2026
- Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesYahoo Finance·Jan 16, 2026
- Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 MillionYahoo Finance·Jan 16, 2026
- Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San FranciscoYahoo Finance·Jan 9, 2026
- Tiziana Life Sciences files annual safety report for intranasal foralumabYahoo Finance·Dec 30, 2025
- Tiziana Files Annual Safety Report for Intranasal Foralumab with FDAYahoo Finance·Dec 29, 2025
- Tiziana Life Sciences Announces Acquisition of Shares by Executive ChairmanYahoo Finance·Dec 19, 2025
- Tiziana Life Sciences to Ring the Closing Bell at NasdaqYahoo Finance·Dec 17, 2025
- Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical TrialYahoo Finance·Dec 17, 2025
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerYahoo Finance·Dec 15, 2025
- Tiziana Life Sciences Announces Withdrawal of Proposed Public OfferingYahoo Finance·Dec 15, 2025
- Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s TrialYahoo Finance·Dec 12, 2025
All 20 articles loaded
Price Data
Open$1.44
Previous Close$1.43
Day High$1.55
Day Low$1.36
52 Week High$2.60
52 Week Low$1.14
52-Week Range
$1.14$2.60
$1.47
Fundamentals
Market Cap$187M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-9.2%
Profit Margin—
Debt / Equity—
Trading
Volume184K
Avg Volume (10D)—
Shares Outstanding127.3M
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—